Ozempic vs. Mounjaro

See how Ozempic and Mounjaro compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Both are once-weekly injections, but Mounjaro activates GIP receptors in addition to GLP-1, a dual mechanism linked to greater average weight loss in trials.

  • Ozempic carries FDA approval for reducing cardiovascular events and slowing kidney disease in type 2 diabetics, uses Mounjaro's label does not currently include.

  • Neither drug is FDA-approved for weight loss on its own; that indication belongs to their sister products, Wegovy and Zepbound.

Ozempic vs. Mounjaro Drug Summary

Ozempic

Ozempic (semaglutide) is a GLP-1 receptor agonist approved to control blood sugar in adults with type 2 diabetes and to reduce cardiovascular and kidney risk in those with existing heart or kidney disease. It is given as a once-weekly subcutaneous injection with a gradual dose increase. Some clinicians prescribe it off-label for weight loss.

Mounjaro

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist approved to control blood sugar in adults and children 10 and older with type 2 diabetes. It is also given as a once-weekly subcutaneous injection with a longer, more gradual titration schedule. It is sometimes prescribed off-label for weight loss, and its sister drug Zepbound carries formal weight-loss approval.

Ozempic vs. Mounjaro Side Effects

Ozempic

Most common
nausea (up to 20.3%)
vomiting (up to 9.2%)
diarrhea (up to 8.8%)
abdominal pain (up to 7.3%)

Mounjaro

Most common
nausea (12-18%)
vomiting (5-9%)
diarrhea (12-17%)
decreased appetite (8-11%)

Ozempic vs. Mounjaro Dosage

Ozempic

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 0.25 mg once weekly Weeks 1-4
Maximum dose 2 mg once weekly If needed
Dose changes 3 increases Every 4 weeks

Mounjaro

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 2.5 mg once weekly Weeks 1-4
Maximum dose 15 mg once weekly Week 21 onward
Dose changes 5 increases Every 4 weeks

Ozempic vs. Mounjaro Indications

Ozempic

Ozempic is FDA-approved to manage blood sugar in adults with type 2 diabetes alongside diet and exercise. It also carries approval to lower the risk of heart attack, stroke, and cardiovascular death in diabetics with known heart disease, and to slow kidney damage in diabetics with chronic kidney disease.

  • Blood sugar control in type 2 diabetes (with diet and exercise)

  • Reduces cardiovascular risk in diabetics with heart disease

  • Slows chronic kidney disease progression in diabetics

  • Off-label: weight loss in people without diabetes

Mounjaro

Mounjaro is FDA-approved to manage blood sugar in adults with type 2 diabetes, and also in children 10 and older with the condition. It does not currently carry approval for cardiovascular or kidney protection.

  • Blood sugar control in adults with type 2 diabetes

  • Blood sugar control in children 10 and older with type 2 diabetes

  • Off-label: weight loss in people without diabetes

  • Related drug Zepbound is approved for weight loss and sleep apnea

Ozempic vs. Mounjaro Pros and Cons

Ozempic

Ozempic has the longer track record of the two, having been on the market since 2017, and its label includes protective effects on the heart and kidneys that Mounjaro's does not. It generally carries a lower list price, though both drugs share similar GI side effects and neither is approved specifically for weight loss.

Pros

  • FDA-approved to reduce cardiovascular events in diabetics with heart disease

  • FDA-approved to slow chronic kidney disease progression

  • Longer real-world track record, approved since 2017

Cons

  • Not FDA-approved for weight loss on its own

  • Single-mechanism GLP-1 agonist, may produce less weight loss than dual agonists

  • Requires separate prescription (Wegovy) if weight loss is the primary goal

Mounjaro

Mounjaro's dual GIP/GLP-1 mechanism has been associated with greater average weight loss in trials compared to GLP-1-only drugs. It is a newer medication with a longer titration schedule, and it does not carry Ozempic's cardiovascular or kidney protection claims.

Pros

  • Dual GIP/GLP-1 mechanism linked to greater average weight loss in trials

  • Approved for pediatric use (age 10+) in type 2 diabetes

  • Sister drug Zepbound carries formal FDA weight-loss approval

Cons

  • Roughly $1,000 to $1,300 per month without insurance, before savings programs

  • Not approved for cardiovascular or kidney risk reduction

  • Newer drug (approved 2022) with a shorter track record

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.